MarketCap
Facebook
X
Telegram
Spero Therapeutics P/E Ratio | SPRO
Annual P/E Ratio Spero Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 15.5 | -1.87 | 3.84 | -1.14 | -4.09 | -4.2 | -2.89 | -3.66 | -0.828 | - | -4.87 | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 15.5 | -4.87 | -0.421 |
P/E Ratio of other stocks in the Biotechnology industry
| Issuer | P/E Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Институт стволовых клеток человека
ISKJ
|
38.8 | - | - | - |  Russia |
 |
Lyra Therapeutics
LYRA
|
-4.96 | - | - | $ 24.9 M |  USA |
 |
Завод ДИОД
DIOD
|
17.7 | - | - | - | Russia |
 |
Фармсинтез
LIFE
|
-3.81 | - | - | - | Russia |
 |
Ionis Pharmaceuticals
IONS
|
-33.9 | $ 43.5 | 0.62 % | $ 6.96 B | USA |
 |
Agios Pharmaceuticals
AGIO
|
-3.95 | $ 31.25 | 0.88 % | $ 1.81 B | USA |
 |
Foghorn Therapeutics
FHTX
|
-4.79 | $ 2.0 | 0.74 % | $ 126 M | USA |
 |
Inhibikase Therapeutics
IKT
|
-3.32 | $ 2.0 | 0.5 % | $ 197 M | USA |
 |
Kamada Ltd.
KMDA
|
24.3 | $ 8.0 | 1.34 % | $ 461 M |  Israel |
 |
Intellia Therapeutics
NTLA
|
-1.88 | $ 12.75 | 4.0 % | $ 1.38 B | USA |
 |
Ultragenyx Pharmaceutical
RARE
|
-3.5 | $ 14.5 | 3.19 % | $ 1.43 B | USA |
 |
Viridian Therapeutics
VRDN
|
-8.73 | $ 19.0 | 2.16 % | $ 1.93 B | USA |
 |
AbbVie
ABBV
|
220 | $ 265.76 | 1.12 % | $ 470 B | USA |
 |
AbCellera Biologics
ABCL
|
-6.57 | $ 13.78 | 0.29 % | $ 4.12 B |  Canada |
 |
Abeona Therapeutics
ABEO
|
-3.54 | $ 5.11 | 1.59 % | $ 271 M | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
-25.3 | $ 4.67 | 4.94 % | $ 895 M | Canada |
 |
ACADIA Pharmaceuticals
ACAD
|
9.33 | $ 20.11 | 0.8 % | $ 3.39 B | USA |
 |
Achieve Life Sciences
ACHV
|
-2.31 | $ 7.01 | 0.13 % | $ 306 M | USA |
 |
AC Immune SA
ACIU
|
-4.08 | $ 2.71 | 0.55 % | $ 273 M |  Schweiz |
 |
Aclaris Therapeutics
ACRS
|
-5.93 | $ 4.27 | 0.79 % | $ 523 M | USA |
 |
Adagene
ADAG
|
-12.7 | $ 2.8 | 0.28 % | $ 165 M |  China |
 |
ADC Therapeutics SA
ADCT
|
-0.971 | $ 1.23 | 8.85 % | $ 156 M | Schweiz |
 |
Adial Pharmaceuticals
ADIL
|
-0.164 | $ 4.35 | 5.58 % | $ 2.91 M | USA |
 |
ADMA Biologics
ADMA
|
25.7 | $ 10.11 | 4.01 % | $ 2.41 B | USA |
 |
Adaptive Biotechnologies Corporation
ADPT
|
-41.7 | $ 29.84 | 5.26 % | $ 4.53 B | USA |
 |
Agenus
AGEN
|
-31.7 | $ 8.73 | 4.43 % | $ 260 M | USA |
 |
AIM ImmunoTech
AIM
|
-0.0812 | $ 0.19 | 5.56 % | $ 308 K | USA |
 |
Akebia Therapeutics
AKBA
|
-63.1 | $ 0.91 | 5.26 % | $ 234 M | USA |
 |
Akari Therapeutics, Plc
AKTX
|
-467 | $ 8.76 | 0.46 % | $ 590 B |  Britain |
 |
Aldeyra Therapeutics
ALDX
|
-9.65 | $ 0.92 | 4.88 % | $ 55.3 M | USA |
 |
Alector
ALEC
|
-1.73 | $ 1.99 | 9.94 % | $ 205 M | USA |
 |
Aligos Therapeutics
ALGS
|
-2.73 | $ 5.4 | 0.36 % | $ 53.4 M | USA |
 |
Alkermes plc
ALKS
|
21.2 | $ 42.76 | 2.42 % | $ 7.04 B |  Irlanda |
 |
Allogene Therapeutics
ALLO
|
-2.85 | $ 1.5 | 0.33 % | $ 331 M | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
130 | $ 219.89 | 0.08 % | $ 28.8 B | USA |
 |
Altimmune
ALT
|
-3.61 | $ 2.67 | 0.36 % | $ 235 M | USA |
 |
ALX Oncology Holdings
ALXO
|
-1.12 | $ 1.21 | 1.23 % | $ 64.9 M | USA |
 |
Amgen
AMGN
|
25.7 | $ 402.98 | 0.08 % | $ 217 B | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
12.7 | $ 25.37 | 0.39 % | $ 1.19 B | USA |
 |
Amarin Corporation plc
AMRN
|
-150 | $ 12.09 | 0.31 % | $ 5.02 B | Irlanda |
 |
Amneal Pharmaceuticals
AMRX
|
59.8 | $ 20.35 | 0.25 % | $ 6.38 B | USA |
 |
AnaptysBio
ANAB
|
12.1 | $ 49.2 | 1.38 % | $ 1.43 B | USA |
 |
Anika Therapeutics
ANIK
|
-19.7 | $ 19.73 | 3.3 % | $ 283 M | USA |
 |
ANI Pharmaceuticals
ANIP
|
15.9 | $ 72.58 | 0.55 % | $ 1.46 B | USA |
 |
Annexon
ANNX
|
-3.72 | $ 4.2 | 0.24 % | $ 651 M | USA |
 |
Annovis Bio
ANVS
|
-1.79 | $ 1.2 | 1.69 % | $ 24.7 M | USA |
 |
Aprea Therapeutics
APRE
|
-0.394 | $ 0.68 | 0.16 % | $ 4.45 M | USA |